Vivos Therapeutics, Inc. 8-K

What Happened
Vivos Therapeutics, Inc. (VVOS) filed a Current Report on Form 8-K on April 15, 2026 (Accession No. 0001493152-26-016865) to announce its financial results for the fiscal year ended December 31, 2025. The company furnished a press release with those results as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: April 15, 2026; fiscal year end reported: December 31, 2025.
• Press release announcing the results is furnished as Exhibit 99.1 to the 8-K.
• The filing includes an Inline XBRL cover page interactive data file (Exhibit 104).
• The company states the furnished information is not “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other SEC filings.

Why It Matters
This 8-K signals that Vivos has publicly released its FY2025 financial performance, which may contain revenue, earnings, cash-flow, or other operational metrics investors use to assess the company’s health and share outlook. Retail investors should review the Exhibit 99.1 press release and any subsequent filings for the specific figures and management commentary to evaluate potential impacts on the stock.